Article
With seven approved drugs for overactive bladder already on the market, the potential for new treatments might seem to be limited. The reality is that OAB treatment is still not optimal.
Enrollment goal met in phase 3 SOLAR-RECUR trial
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
FDA accepts sNDA for darolutamide plus ADT in mHSPC
Key updates from the AUA/ASRM male infertility guideline amendment
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
Dean Laganosky, M.D., named Urology Trailblazer for 2024